Agreement - April 6, 2022
Idogen signs agreement with two Nordic CROs
Idogen has signed a strategic collaboration agreement with two contract research organizations, Danish Klifo and Finnish 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8. IDO 8 is a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The […]
Acquisition - May 7, 2021
Gilde Healthcare acquires majority stake in KLIFO
Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a drug development consultancy, have announce that Gilde’s Private Equity fund has acquired a majority stake in KLIFO. Gilde Healthcare aims to support KLIFO’s growth in the dynamically developing pharma outsourcing sector, the companies state in a press release. Alejandra Mørk will continue as CEO of […]